Dr. Randy Allison Taplitz, MD

Dr. Taplitz practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Taplitz's NPI, 1013925551, was assigned on August 3, 2006. Dr. Taplitz graduated from UCSF School of Medicine in 1988. Dr. Taplitz's California license number on file is G67522.

Dr. Taplitz's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Taplitz's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. The medical group on file is UC San Diego Health. Dmand AI also links Dr. Taplitz to 1 more other site and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Taplitz practices. Vendor and product names are available with a free account.

Infectious disease is Dr. Taplitz's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Taplitz is board certified in infectious disease by the American Board of Internal Medicine. Dmand AI has Dr. Taplitz's licenses on file in 2 states: California and Oregon.

CMS data shows 85 Medicare services from Dr. Taplitz across 2 procedure codes in 2024, for 35 Medicare patients. Medicare paid $9,350 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 35 Medicare patients who saw Dr. Taplitz in 2024. The largest group is 65 to 74, with 18 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 46% are also on Medicaid. Their average risk score is 5.25, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Taplitz's median patient age at 63, with 40% women.

In 2020, Dr. Taplitz wrote 45 Medicare Part D claims. They cover 3 drugs, with $1,773 in total drug cost. In 2019, CMS named 46 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Taplitz for performance year 2024, reported as part of a group. Dr. Taplitz accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 78 papers to Dr. Taplitz, published from 2006 to 2024. 2018 was the busiest year, with 9. The most frequent topics are Anti-Bacterial Agents, Hematopoietic Stem Cell Transplantation and California. Dr. Taplitz has published most often in J Immunol. Dr. Taplitz's most frequent co-authors are Sanjeet Singh Dadwal, MD, Deepa Dharshani Nanayakkara and Jana Kubrin Dickter, MD.

Dmand AI links Dr. Taplitz to 4 clinical trials. 1 is still active or recruiting. Conditions studied include Adenoviridae Infections, COVID-19 and DNA Virus Infections. Chimerix sponsors the most, 3.

CMS Open Payments shows 30 general payments to Dr. Taplitz from 4 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 56% of the total. Merck Sharp & Dohme Corporation paid the most, $10,795.

Dmand AI lists 1 award for Dr. Taplitz, most recently CMS Stage 1 EHR in 2013.

Dr. Taplitz graduated from UCSF School of Medicine in 1988.

Dr. Taplitz is in network with 11 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.